This week on DocWire, editors spoke with Giovanni Di Napoli, President of Medtronic Gastrointestinal, about GI Genius, an intelligent endoscopy that uses artificial intelligence to identify colorectal cancer (CRC) that was recently cleared by U.S. FDA. In a randomized, controlled trial, use of GI Genius during endoscopy colonoscopy improved lesion detection by 14.4% compared with standard colonoscopy.
In other news, renal cell carcinoma risk is higher among Hispanic Americans and Native Americans than white Americans, according to a recent study published in the journal Cancers. “We knew from our past research that Hispanic Americans and Native Americans have a heavier burden of kidney cancer than non-Hispanic whites,” said study co-author Ken Batai, PhD. “But we also know that around 90% of the Hispanic population in Arizona is Mexican American – either U.S.-born or Mexican-born – and we do not think this subgroup is well-represented in the national data.”
Using CRISPR-Cas 9 screens, researchers were able to identify genetic determinants of response and resistance to commonly used drugs to treat multiple myeloma. Fifteen mutations were functionally linked to resistance for myeloma drugs, including lenalidomide, bortezomib, dexamethasone, and melphalan. The investigators also reported that inactivation of genes in the DNA damage repair pathway were linked to increased response to cytotoxic chemotherapy.
A study found that patients with cancer are feeling especially lonely and depressed amid the COVID-19 pandemic. According to the results, over half (53%) of patients were experienced loneliness, which was higher than reported prior to the pandemic (32–47%). About a third had moderately high degrees of loneliness, and 5.3% reported high levels of depression